In their study of the American population (482 men with prostate cancer and 189 men without cancer), Scott et al. found MT-CO1 polymorphisms in 8.8% of Caucasian patients with prostate cancer and 72.8% of patients of African descent. Here, MCAT is linked to prostate cancer.